Dai Ichi Life Insurance Company, LTD Biomarin Pharmaceutical Inc Transaction History

Dai Ichi Life Insurance Company, LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$71.87 - $131.03 $1.01 Million - $1.83 Million	-13,991 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$79.55 - $124.22 $32,217 - $50,309	-405 Reduced 2.81%	13,991 $1.73 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $4.2 Million - $4.91 Million	-52,252 Reduced 78.4%	14,396 $1.23 Million
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $1.31 Million - $1.53 Million	15,509 Added 30.33%	66,648 $5.92 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $33,097 - $43,806	-413 Reduced 0.8%	51,139 $4.35 Million
Q3 2018 Nov 13, 2018	BUY	$93.92 - $105.72 $633,208 - $712,764	6,742 Added 15.05%	51,552 $5 Million
Q2 2018 Aug 10, 2018	BUY	$76.01 - $99.03 $2.61 Million - $3.4 Million	34,341 Added 328.03%	44,810 $4.22 Million
Q4 2017 Feb 13, 2018	SELL	$80.76 - $95.13 $2.34 Million - $2.76 Million	-29,008 Reduced 73.48%	10,469 $934,000
Q3 2017 Nov 09, 2017	BUY	$80.6 - $94.95 $3.18 Million - $3.75 Million	39,477	39,477 $3.67 Million

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Dai Ichi Life Insurance Company, LTD, based on Form 13F filings with the SEC.

Stay updated on Dai Ichi Life Insurance Company, LTD with notifications on news.